Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding their preference to continue or discontinue beta-blockers in older adults with Heart Failure with Preserved Ejection Fraction (HFpEF).
Ambulatory adults age ≥ 65 years with HFpEF, according to ACC/AHA guidelines (signs and symptoms of heart failure AND ejection fraction ≥ 50%)
Taking beta-blocker
Severe aortic stenosis
Moderate-severe mitral stenosis
Constrictive pericarditis
High output HF
Weill Medical College of Cornell University
Lead sponsor
National Institute on Aging (NIA)
Collaborator